Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jessie Kim

Nurse Practitioner, Adult Health New York, NY Nurse Practitioner

NPI 1831426709 CMS profile 11251123

First Ave At 16Th Street, New York, NY 10003

Open in the dashboard

General payments

$7,022

147 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jessie Kim of New York, NY is reported in the CMS Open Payments database as having received $7,022 across 147 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $690 16
2024 General $1,246 38
2023 General $3,138 48
2022 General $1,621 34
2021 General $327 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jessie Kim
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Jessie Kim were reported at $690. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Jessie Kim Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $327 $138 $43–$438 $132
2022 $1,621 $165 $54–$494 $149
2023 $3,138 $178 $61–$549 $160
2024 $1,246 $186 $62–$575 $164
2025 $690 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $1,923 48 payments
  2. Medtronic, Inc. $1,692 22 payments
  3. Janssen Pharmaceuticals, Inc $1,092 11 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $712 9 payments
  5. Lexicon Pharmaceuticals, Inc. $382 18 payments
  6. Abbott Laboratories $290 3 payments
  7. Novartis Pharmaceuticals Corporation $286 15 payments
  8. Merck Sharp & Dohme Corporation $267 8 payments
  9. Novo Nordisk Inc $125 1 payment
  10. E.R. Squibb & Sons, L.L.C. $83 5 payments
  11. Other $171 7 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,994 140 payments
  2. Travel and Lodging $1,027 7 payments
Products named General payments · program years 2021–2025
  1. XARELTO $1,092 11 payments
  2. General - Therapies $683 7 payments
  3. JARDIANCE Diabetes $443 6 payments
  4. LUX-Dx Insertable Cardiac Monitor $417 11 payments
  5. LATITUDE Communicator Power Supply $292 11 payments
  6. JARDIANCE Diabetes $269 3 payments
  7. VERQUVO $267 8 payments
  8. Inpefa $203 7 payments
  9. MITRACLIP $150 1 payment
  10. Ozempic $125 1 payment
  11. Other $999 49 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

129

Median for Nurse Practitioner: 389

Drug cost

$72,757

Median for Nurse Practitioner: $21,885

Branded share of claims

62%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 35 $35,010
Xarelto Rivaroxaban Brand 22 $28,391
Jardiance Empagliflozin Brand 11 $8,583
Amiodarone Hcl Generic 14 $292
Metoprolol Succinate Generic 24 $278
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 12 $163
Amlodipine Besylate Generic 11 $40

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $401
$401 22 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $125
$125 11 —
Inpefa
  • Lexicon Pharmaceuticals, Inc. $113
$113 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

147 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record